News

Pfizer and Medivation have reported the initiation of Contact and Constellation, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD).

Idera Pharmaceuticals (Idera) has provided preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). IMO-2125 is a novel

Teva Pharmaceutical (Teva) reported a profit of $649m for the third quarter of 2009, compared with $631m in third quarter of 2008. The company reported net sales of

Addex has presented results from studies of its lead clinical candidate, ADX10059, in animal models of parkinson’s disease levodopa induced dyskinesia (PD-LID) at the Discovery on Target GPCR-based

Symphogen has opened its US headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed chief business officer, will head the company’s US business which will operate as

The patented TruTip approach uses a nucleic acid binding matrix that is easily inserted into most standard pipette tips, including those used by electronic pipettes and liquid handling

SurModics and NuPathe have entered into a license agreement for drug delivery technology. The companies aim to develop NuPathe’s NP201, the first long-acting treatment available in broadly acceptable

Biomarkers are small molecules that indicate the presence of a particular physiological condition, typically a disease. The new method, if successful, could prove useful not just for identifying

Idenix Pharmaceuticals (Idenix) has initiated a phase II randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of IDX184 in combination with